100% Quality Guarantee
PhD-Level Technical Support
Efbalropendekin Alfa (Research-Grade)
Key Features

Efbalropendekin Alfa (Research-Grade) (GXBS02099)

SKU GXBS02099
Product Type Research Grade Biosimilar
Antibody Type Monoclonal
Reactivity Human
Applications ELISA, Functional assay, Research in vivo
Isotype Human interleukin-15/IL-15 fragment variant fused via peptide linker to a human IgG1 C-terminal Fc fragment disulfide bridge with human interleukin-15 receptor subunit alpha fragment fused via a peptide linker to a human immunoglobulin G1 Fc fragment
$832 - $2,827

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheetsystem_update_altMSDS

Efbalropendekin Alfa (Research-Grade)

Efbalropendekin Alfa (Research-Grade) is a research-grade biosimilar monoclonal antibody targeting CD215. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.

Efbalropendekin Alfa (XmAb24306) is an IL-15/IL-15 receptor alpha complex fused to a heterodimeric Fc domain (IL15/IL15Rα-Fc). Efbalropendekin Alfa increases direct and antibody-dependent cellular cytotoxicity (ADCC)-mediated human natural killer (NK) cell cytotoxicity in vitro.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose